A Phase 2 RCT Study of CX-8998 for Essential Tremor

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

July 16, 2018

Study Completion Date

July 16, 2018

Conditions
Essential Tremor
Interventions
DRUG

CX-8998

T-type calcium channel blocker

DRUG

Placebo

Placebo comparator

Trial Locations (22)

10032

Columbia University, New York

27612

Wake Research Associates, LLC, Raleigh

30329

Emory University School of Medicine, Atlanta

31406

Meridian Neurology Clinical Research, Savannah

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33612

University of South Florida, Tampa

37232

Vanderbilt University, Nashville

45417

Midwest Clinical Research Center, Dayton

48109

University of Michigan, Ann Arbor

48322

Henry Ford Hospital West Bloomfield, West Bloomfield

48334

Quest Research Institute, Farmington Hills

60611

Northwestern Medical Group, Chicago

63110

Washington University School of Medicine, St Louis

63141

St. Louis Clinical Trials, St Louis

66160

University of Kansas Medical Center, Kansas City

72211

Woodland International Research Group, Little Rock

72758

Woodland Research Northwest, Rogers

77030

Houston Methodist Neurological Institute, Houston

85710

Tucson Neuroscience Research, Tucson

92093

University of California San Diego, La Jolla

92103

Pacific Research Network, San Diego

02118

Boston University Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY